Marrone KA, et al. - In this phase II study, the 1-year progression free survival (PFS), overall survival, response to therapy, and toxicity in patients who received carboplatin, paclitaxel, and bevacizumab with or without concurrent metformin, followed by maintenance therapy with bevacizumab ± metformin was assessed for chemotherapy-naïve advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). With the use of metformin, a significant benefit in PFS was noted in this patient population, suggesting efficacy for metformin in advanced NSCLC.